Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

A. T. Paquete; M. Gouveia; R. Guerreiro; J. Anjo; C. Magalhaes; M. Borges

Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

A. T. Paquete^*
, M. Gouveia
, R. Guerreiro
, J. Anjo
, C. Magalhaes
, M. Borges

^*Corresponding author for this work

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	PCN67
Pages (from-to)	S448-S448
Number of pages	1
Journal	Value in Health
Volume	22
Issue number	S3
Publication status	Published - Nov 2019
Event	ISPOR Europe 2019 - Bella Center Copenhagen, Copenhagen, Denmark Duration: 2 Jan 2019 → 6 Nov 2019

Cite this

@article{92adbf2cf78e49b2b5bf6b2b43143de7,

title = "Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal",

author = "Paquete, \{A. T.\} and M. Gouveia and R. Guerreiro and J. Anjo and C. Magalhaes and M. Borges",

year = "2019",

month = nov,

language = "English",

volume = "22",

pages = "S448--S448",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

number = "S3",

note = "ISPOR Europe 2019 ; Conference date: 02-01-2019 Through 06-11-2019",

}

Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal. / Paquete, A. T.; Gouveia, M.; Guerreiro, R. et al.
In: Value in Health, Vol. 22, No. S3, PCN67, 11.2019, p. S448-S448.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

AU - Paquete, A. T.

AU - Gouveia, M.

AU - Guerreiro, R.

AU - Anjo, J.

AU - Magalhaes, C.

AU - Borges, M.

PY - 2019/11

Y1 - 2019/11

M3 - Meeting Abstract

SN - 1098-3015

VL - 22

SP - S448-S448

JO - Value in Health

JF - Value in Health

IS - S3

M1 - PCN67

T2 - ISPOR Europe 2019

Y2 - 2 January 2019 through 6 November 2019

ER -